Syngene International Limited — PPTs, 24-07-2025: Investor Presentation

Here's a summary of the attached document:

**Financial Highlights:**

Syngene reported Q1 FY26 revenue from operations of Rs 874.5 Cr, up 11% year-over-year. Profit before exceptional items surged 59% year-over-year to Rs 86.7 Cr, with Operating EBITDA margin expanding to 23.6% (from 21.5% in Q1 FY25). The company maintains robust shareholders' funds of Rs 4,846.3 Cr and a net cash position of Rs 1,052.8 Cr.

**Strategic Initiatives & Growth Drivers:**

The company inaugurated a new, state-of-the-art dedicated peptide laboratory, enhancing capabilities in rapidly growing interventional modalities. Strategic focus continues on end-to-end therapeutic discovery services and establishing integrated small and large molecule development and manufacturing. Digital transformation and AI integration are key enablers for future growth.

**Business Developments:**

Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. Its Biologics facility received an Establishment Inspection Report (EIR) with a favorable Voluntary Action Indicated (VAI) outcome. The company concluded over 20 client and regulatory audits in the quarter.

**Market Position & Competitive Advantage:**

Recognized as a global scale CRDMO player, Syngene leverages 5,600+ scientists and serves ~400 active clients, including 14 of the top 20 pharma companies. Its facilities are globally compliant with approvals from USFDA, EMA, and others. Syngene was awarded by TIME magazine and Statista as one of the World’s Most Sustainable Companies in 2025, ranking #1 in India among pharma and biotech sectors.

**Investor Implications:**

Strong Q1 financial performance, coupled with strategic capability expansion and robust regulatory compliance, indicates positive growth potential for Syngene.